BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection...
Hence then, the article about once monthly glp 1 ra gan lee pharmaceuticals initiates phase 3 clinical study gradual 3 of the first chinese once monthly glp 1 ra for weight management was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Once-Monthly GLP-1 RA .. Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management )
Also on site :
- Tornado warning issued, and quickly cancelled, over Alhambra
- Governor Hochul: Annual statewide donation drive is complete
- Skier dies in collision with tree at Colorado’s Aspen Mountain, resort officials confirm